Aptus Pharma Limited's Board has approved raising ₹44.88 Crore through a preferential equity issue. Funds will support manufacturing capacity expansion, working capital, and Pan-India growth initiatives.
Aptus Pharma Limited submitted its Monitoring Agency Report for the period ended March 31, 2026, confirming full utilization of ₹13.02 Crore raised through its IPO. The report, issued by CARE Ratings Limited, shows NIL deviation from the objects stated in the offer document, covering working capital, capital expenditure, and corporate purposes.
